EpiVax Progresses on a Vaccine to Address SARS-CoV-2 Variants

by Elena Iemma | Nov 30, 2021 | News

PROVIDENCE, RI, November 30, 2021 /PRNewswire/ — Today EpiVax, Inc. (“EpiVax”) confirmed that the company’s EPV-CoV-19 vaccine epitope sequences are 98.2% conserved in the new Omicron SARS-CoV-2 variant. EpiVax and EpiVax Therapeutics, Inc....

EpiVax Collaborates with Leidos on Malaria Vaccine Research, Series of Papers Published in Frontiers In Immunology

by Elena Iemma | Nov 17, 2021 | News

PROVIDENCE, RI, November 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication of three papers focusing on malaria vaccine efficacy, part of a collaboration with Leidos, the University of Georgia Center for Vaccines and Immunology, the University...

EpiVax Licenses Tregitope Technology to Maruho Co., Ltd. for development of Tregitope-based Therapies to Treat Autoimmune Condition

by Elena Iemma | Nov 4, 2021 | News

PROVIDENCE, RI, November 4, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce an important commercial licensing agreement with Maruho Co., Ltd. (“Maruho”) for EpiVax’s patented Tregitope technology. This marks an exciting step for Maruho and...

Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax

by Elena Iemma | Jul 6, 2021 | News

PROVIDENCE, RI, July 6, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce that Dr. Amy Rosenberg is leaving the FDA’s Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as Senior Director of Immunology and...

EpiVax Identifies T cell Epitopes critical to robust T cell immune response in SARS-CoV-2 , Results Published in NPJ Vaccines

by Elena Iemma | May 17, 2021 | News

PROVIDENCE, RI, May 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation” in NPJ Vaccines. This research identifies...